Johnson & JohnsonNYSE: JNJ
Health Care · Pharmaceuticals
$237.09
+2.31%
Vol: 967K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14Johnson & Johnson expands its oncology pipeline with a $1 billion acquisition of Firefly Bio targeting hard-to-drug cancer targets.Positive▶
Johnson & Johnson agreed to acquire Firefly Bio for about $1 billion, gaining technology aimed at one of cancer's most "undruggable" targets, deepening its oncology portfolio. The move accompanies positive Phase 3 MajesTEC-9 data for TECVAYLI (teclistamab) monotherapy in relapsed or refractory multiple myeloma, showing a substantial reduction in risk of disease progression or death versus standard of care. J&J also expanded US availability of its FDA-approved TECNIS PureSee intraocular lens and was named the top healthcare company on the WSJ's 2026 Best Companies for the Future list. The stock rose about 1.07% in the latest session. Why it matters: bolt-on M&A and pivotal trial wins support the growth pipeline. The risk is investor caution on execution despite raised guidance.
May 21JNJ's investigational Ottava robotic surgery system meets primary endpoints in gastric bypass study; psoriasis pill expected to be among biggest drugs everPositive▶
Johnson & Johnson announced its investigational Ottava robotic surgery system met primary endpoints in a clinical study evaluating safety/performance in Roux-en-Y gastric bypass through 30 days post-procedure. CNBC reported May 16 that J&J's new psoriasis pill could be one of its biggest drugs ever. J&J recently received approvals including ICOTYDE in the US for moderate-to-severe plaque psoriasis and VARIPULSE Pro in Europe. The company participated in the RBC Global Healthcare Conference May 19. Q1 2026 sales grew 9.9% with management raising 2026 guidance midpoints by 30bps (to 7% sales) and 20bps (to 5.7% adj. EPS). Quarterly dividend raised 3.1% to $1.34, marking the 64th consecutive year of increases. Stock at $229.535 (+2.35%), avg PT $258.36.
May 20J&J's Ottava surgical robot hits primary endpoints in gastric-bypass trial, positioning it to challenge Intuitive Surgical as Leerink upgrades to Outperform at $265.Positive▶
Johnson & Johnson announced its investigational Ottava soft-tissue robotic surgery system met primary endpoints in its first clinical study evaluating safety and performance in Roux-en-Y gastric bypass procedures, with FDA approval expected in 2026. The milestone positions J&J to enter a robotic surgery market long dominated by Intuitive Surgical's da Vinci. On May 13, Leerink upgraded JNJ to Outperform from Market Perform with a $265 price target (up from $252). Q1 revenue of $24.06B drove raised full-year guidance to $99.7-100.7B, and the board lifted the quarterly dividend 3.1% to $1.34 (ex-date May 26), marking the 64th consecutive annual increase. J&J also closed/completed its Atraverse Medical acquisition. The new psoriasis pill is expected to be one of its biggest drugs ever. Risks remain tied to ongoing talc litigation exposure and competitive launches.
May 19Leerink upgraded J&J to Outperform on new drug momentum as the Ottava surgical robot hit its primary endpoint and Tremfya Phase 3 FUZION data reported out.Positive▶
Leerink upgraded Johnson & Johnson to Outperform on May 13, 2026, citing momentum across the pipeline. J&J announced that its investigational Ottava soft-tissue surgical robotic system met its primary endpoints in its first clinical study for Roux-en-Y gastric bypass through 30 days post-procedure, with expected approval in 2026. The company also reported Phase 3 FUZION results for Tremfya and Phase 2b data from JNJ-4804, and shared favorable IMPACT trial data for Abiomed's Impella 5.5 in high-risk cardiac surgery patients. J&J declared a $1.34 cash dividend with a May 26 ex-date and is closing the Atraverse Medical acquisition in Q2. Bear case: ongoing talcum powder litigation, biosimilar erosion of legacy biologics, and competitive pressure on Stelara/Tremfya pricing remain headwinds.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15J&J upgraded by Leerink on new drug launches as OTTAVA robotic surgery hits primary endpoints and dividend is raised 3.1%Positive▶
On May 13, Leerink Partners upgraded JNJ to Outperform from Market Perform, citing growth prospects from newly approved Icotyde and Inlexzo. On May 5, J&J announced its investigational OTTAVA Robotic Surgical System met primary safety and performance endpoints in a 30-patient gastric bypass study with all procedures completed robotically without conversion. The board raised the quarterly dividend 3.1% to $1.34 (64th consecutive annual increase), with an ex-date of May 26. The company also reported Phase 3 FUZION data for Tremfya and Phase 2b JNJ-4804 results, plus a U.S. pilot study supporting Impella 5.5 in high-risk cardiac surgery. UBS, HSBC, Guggenheim, Barclays, Stifel, Morgan Stanley, RBC and Citi raised price targets, several to $280. Shares are at $230.31 with a $238 consensus PT.
May 14JNJ rallies 2.8% on May 13 after Leerink and Johnson Rice upgrade to Outperform citing newly approved Icotyde (oral psoriasis peptide) and Inlexzo as growth re-rating drivers.Positive▶
On May 13, 2026, Leerink Partners upgraded Johnson & Johnson to Outperform from Market Perform, and Johnson Rice followed with a similar upgrade from Hold, both citing growth from newly approved products Icotyde (icotrokinra, oral plaque psoriasis peptide approved by FDA in March 2026) and Inlexzo. Shares jumped 2.8% intraday, trading as high as $230.80 and last at $230.43. Analysts forecast $405M in Icotyde sales in FY26 — 50% above consensus — and raised five-year sales growth targets by 24-34% annually. Q1 2026 EPS was $2.70 vs $2.68 consensus on $24.06B revenue (vs $23.60B est). The quarterly $1.34 dividend goes ex on May 26. Risk: the re-rating thesis depends on continued strong uptake of new launches; underlying base businesses still face biosimilar headwinds, and the consensus is only catching up to a stock that has already rallied 43% over 12 months.
May 13J&J announced positive pivotal OTTAVA robotic surgical system clinical results May 5 (30 of 30 procedures completed without conversion) with 2026 approval expected; presenting at BofA healthcare conference May 12 and RBC May 19.Positive▶
Johnson & Johnson announced May 5 the first clinical study results for its investigational OTTAVA Robotic Surgical System in Roux-en-Y gastric bypass procedures, with all 30 patients completed robotically without conversion and primary safety/performance endpoints met at 30 days; J&J expects FDA approval in 2026. On May 7 the company launched the "Generation Fine" global depression-care campaign. JNJ presented at the BofA Global Healthcare Conference May 12 (John Reed, EVP Innovative Medicine and R&D), and will present at the RBC Global Healthcare Conference May 19. The company will present 18 abstracts of neuropsychiatry data at the APA Annual Meeting (May 16-20) and ASCP (May 26-29). Shares trade at $222-227 with a $536B market cap and a $1.34 dividend ex-date May 26. Q1 saw the FDA approval of Icotyde (Icotrokinra) for plaque psoriasis (a first-in-class oral peptide).
May 12J&J's OTTAVA robotic surgical system met primary safety/performance endpoints in its first clinical study of Roux-en-Y gastric bypass procedures, with approval expected in 2026; shares trade ~$222.51.Positive▶
On May 5, J&J announced positive 30-day results from the first clinical study of its investigational OTTAVA Robotic Surgical System in gastric bypass, with all procedures completed robotically without conversion - approval is targeted for 2026. On May 11, the company disclosed 18 abstracts from its neuropsychiatry portfolio for presentation at the APA (May 16-20) and ASCP (May 26-29) meetings. New IMPACT pilot data supported the Abiomed Impella 5.5 system in high-risk cardiac surgery patients. JNJ declared a $1.34 dividend (ex-date May 26). Stock is up ~43% over the past year, trading at a P/E of 25.5x vs. a 3-year average of 20.6x, with revenue growth of 7.9% LTM.
May 11J&J's investigational Ottava soft-tissue surgical robot met its primary endpoints in a pivotal study reported May 5, positioning the company to challenge Intuitive Surgical's da Vinci, while an IBD therapy missed its primary endpoint the same day.Mixed▶
On May 5, J&J announced its Ottava robotic surgery system met primary endpoints in its first pivotal study (safety/performance in Roux-en-Y gastric bypass through 30 days post-procedure), with management expecting approval sometime in 2026 - a key entry into the robotic surgery market historically dominated by Intuitive Surgical. Separately, J&J's closely watched IBD therapy failed to show statistically meaningful improvement in its trial reported May 5, though the company plans to advance the drug into late-stage testing in a defined subgroup. J&J also released positive cardiac surgery data from its Abiomed Impella 5.5 IMPACT pilot study, and launched a global depression-awareness campaign called Generation Fine. The board declared a 3.1% dividend increase to $1.34/share (64th consecutive year of increases), ex-date May 26. Shares trade around $222 with market cap ~$536B. Key risk: 2026 guidance already absorbs hundreds of millions of dollars of Trump-administration drug pricing impact plus the CVS Stelara formulary drop.
May 8OTTAVA Robotic Surgical System cleared primary safety/performance endpoints in 30-patient gastric bypass study; JNJ-4804 IBD therapy shows meaningful improvements; dividend raised to $1.34 ex-date May 26.Positive▶
Johnson & Johnson announced pivotal clinical results for its OTTAVA Robotic Surgical System, with a 30-patient multicenter study meeting primary safety and performance endpoints in Roux-en-Y gastric bypass procedures with zero conversions to non-robotic approaches by 30 days post-procedure. Phase 2b data for JNJ-4804, an investigational co-antibody therapy targeting IL-23 and TNF-alpha, showed meaningful improvements in ulcerative colitis and Crohn's disease at Week 48 across multiple clinical and endoscopic measures. Q1 2026 demonstrated strong performance with Darzalex and Erleada driving oncology growth. JNJ announced a $1.34 quarterly dividend with ex-date of May 26, continuing its status as a Dividend King with 64 consecutive years of increases. Current stock price is $222.28, down slightly (-0.94% in 24 hours, -2.39% weekly) but up 42.65% year-over-year.
May 6J&J Ottava robotic surgery system hits key regulatory milestone; Atraverse Medical acquisition underwayPositive▶
Johnson & Johnson announced investigational Ottava robotic surgery system achieved critical milestone with expected FDA approval in 2026, supporting double-digit revenue growth goal by decade's end. Company agreed to acquire Atraverse Medical for electrophysiology left-heart access and RF technologies; deal closing expected Q2 2026. Q1 2026 revenue of $24.06B, raised FY2026 sales outlook.
May 5Johnson & Johnson Q1 2026 revenue $24.06B beats; full-year guidance raised to $100.3-$100.4BPositive▶
Johnson & Johnson reported strong first-quarter 2026 results with revenue of $24.06 billion and raised full-year sales outlook to $100.30-$100.40 billion. The company achieved positive momentum with FDA approvals including Caplyta showing greater efficacy in major depressive disorder and Imaavy granted Priority Review for hemolytic anemia. JNJ signed onto the TrumpRx.gov federal discount program, listing four popular drugs including metformin, Invokana, and Xarelto. The company is investing $55 billion to expand R&D sites in Pennsylvania and North Carolina. JNJ's Abiomed unit released positive clinical data for its Impella 5.5 system in non-shock, high-risk cardiac patients. The stock closed May 1 at $227.19 with 46.59% 52-week gains but -7.49% month-to-date decline. Analyst sentiment remains cautiously optimistic despite ongoing legal challenges including 3,000+ U.K. asbestos talc claimants and 50,000+ total claims.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $1,119.42 | +7.47% | +5.4% | 23.4x | 0.48 | $928.9B |
| JNJJOHNSON | $237.09 | +2.31% | +1.2% | 18.2x | 0.26 | $557.8B |
| MRKMERCK | $115.54 | -0.29% | +3.0% | 12.2x | 0.20 | $286.2B |
| PFEPFIZER | $26.31 | +1.39% | +2.5% | 9.2x | 0.30 | $147.9B |
| BMYBRISTOL | $56.21 | -5.61% | +3.9% | 9.7x | 0.26 | $121.6B |
| ZTSZOETIS | $80.55 | +0.60% | +3.0% | 10.8x | 0.86 | $33.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.